HDL/LDL – wie hoch, wie niedrig?

Schlüsselwörter

kardiovaskuläre Risikofaktoren - HDL-Cholesterin - LDL-Cholesterin - Grenzwert

Keyword

cardiovascular risk factors - HDL cholesterol - LDL cholesterol - cut-off

• Literatur

• 1 Barter PJ, Caulfield M, Eriksson M et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357: 2109-2122
• 2 Bruckert E, Labreuche J, Amerenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 2010; 210: 353-361
• 3 Brugts JJ, Yetgin T, Hoeks SE et al. The benefits of statins in people without established cardiovascular disease but with risk factors: meta-analysis of randomised controlled trials. BMJ 2009; 338: b2376
• 4 Cannon CP, Shah S, Dansky HM et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010; 363: 2406-2415
• 5 Cholesterol Treatment Trialists' Collaboration. Efficacy an safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278
• 6 Cholesterol Treatment Trialists‘ (CTT) Collaboration. Efficacy and safety of more intensive LDL-lowering therapy: meta-analysis of individual data from 170,000 participants in 26 randomised trials of statin therapy. Lancet 2010; 376: 1670-1681
• 7 Di Angelatonio E, Sarwar N, Perry P et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009; 302: 1993-2000
• 8 Holme I, Aastveit AH, Hammar N et al. Relationships between high-density lipoproteins and risk of ischaemic and haemorrhagic stroke in the Apolipoprotein MOrtality Risk Study (AMORIS). J Intern Med 2009; 265: 275-287
• 9 Jun M, Foote C, Lu J et al. Effects of fibrates on cardiovascular outcome: a systematic review and meta-analysis. Lancet 2010; 375: 1875-1884
• 10 Lewington S, Whitlock G, Clarke R et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007; 370: 1829-1839
• 11 Parish S, Peto R, Palmer A et al. The joint effects of apolipoprotein B, apolipoprotein A1, LDL cholesterol and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls. Eur Heart J 2009; 302: 137-146
• 12 Pedersen TR, Faergeman O, Kastelen JJP et al. High-dose atorvastatin versus usual dose simvastatin for secondary prevention after myocardial infarction. The IDEAL study: a randomized controlled trial. JAMA 2005; 294: 2437-2445
• 13 Reiner Z, Catapano AL, De Backer G et al. ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J 2011; 32: 1769-1818
• 14 SHARP Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Lancet 2011; 377: 2181-2192
• 15 Weichhart T, Kopecky C, Kubicek M et al. Serum amyloid A in uremic HDL promotes inflammation. J Am Soc Nephrol 2012; 23: 934-947
• 16 Woodward M, Barzi F, Feigin V et al. Association between high-density lipoprotein cholesterol and both stroke and coronary heart disease in the Asia Pacific region. Eur Heart J 2007; 28: 2653-2660